연구동향 분석

Gene Therapy Options as New Treatment for Inherited Peripheral Neuropathy

Rajarathinam Thenmozhi 이지수 박나영 최병옥 홍영빈 2020년

논문상세정보
인용/피인용
' Gene Therapy Options as New Treatment for Inherited Peripheral Neuropathy' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Antisense oligonucleotide
  • Gene editing
  • Gene therapy
  • Inherited peripheral neuropathy
  • mirna
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
132 0

0.0%

' Gene Therapy Options as New Treatment for Inherited Peripheral Neuropathy' 의 참고문헌

  • miR-381 Attenuates Peripheral Neuropathic Phenotype Caused by Overexpression of PMP22
    이지수 [2019]
  • Viral vectors : the road to reducing genotoxicity
    David RM [2017]
  • TrkB and TrkC agonist antibodies improve function, electrophysiologic and pathologic features in Trembler J mice
    Sahenk Z [2010]
  • Trembler mouse carries a point mutation in a myelin gene
    Suter U [1992]
  • Treatment of infantile-onset spinal muscular atrophy with nusinersen : a phase 2, open-label, dose-escalation study
    Finkel RS [2016]
  • Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease(CMT-1A)
    Sereda MW [2003]
  • The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors
    Emery DW [2011]
  • The peripheral myelin gene PMP-22/GAS-3 is duplicated in Charcot-Marie-Tooth disease type 1A
  • The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A
    Patel PI [1992]
  • Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice
    Lee JS [2020]
  • State-of-the-art human gene therapy:part II. Gene therapy strategies and clinical applications
    Wang D [2014]
  • Stable RNA interference rules for silencing
    Fellmann C [2014]
  • Soluble neuregulin-1modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A
    Fledrich R [2014]
  • Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice
    Nóbrega C [2013]
  • Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown
    Moore CB [2010]
  • Schwann cell targeting via intrasciatic injection of AAV8 as gene therapy strategy for peripheral nerve regeneration
    Homs J [2011]
  • Safety of antisense oligonucleotide and siRNA-based therapeutics
    Chi X [2017]
  • Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model
    Zhou Y [2019]
  • Regulation of the neuropathy-associated Pmp22 gene by a distal super-enhancer
    Pantera H [2018]
  • Reduction of Dicer impairs Schwann cell differentiation and myelination
    Verrier JD [2010]
  • RNA targeting therapeutics : molecular mechanisms of antisense oligonucleotides as a therapeutic platform
    Bennett CF [2010]
  • Potential and challenges of aptamers as specific carriers of therapeutic oligonucleotides for precision medicine in cancer
    Nuzzo S [2019]
  • Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin
    Carroll JB [2011]
  • Polytherapy with a combination of three repurposed drugs(PXT3003)down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy
    Chumakov I [2014]
  • Pmp22 mutant allele-specific siRNA alleviates demyelinating neuropathic phenotype in vivo
    Lee JS [2017]
  • Pharmacological induction of the heat shock response improves myelination in a neuropathic model
    Rangaraju S [2008]
  • Peripheral myelin protein 22 is regulated posttranscriptionally by miRNA-29a
    Verrier JD [2009]
  • PMP22 carrying the trembler or trembler-J mutation is intracellularly retained in myelinating Schwann cells
    Colby J [2000]
  • PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models
    Zhao HT [2018]
  • Nusinersen versus sham control in later-onset spinal muscular atrophy
    Mercuri E [2018]
  • Normalization of overexpressed α-synuclein causing Parkinson's disease by a moderate gene silencing with RNA interference
    Takahashi M [2015]
  • Non-viral gene delivery systems for tissue repair and regeneration
    Wu P [2018]
  • Nextgeneration sequencing in Charcot-Marie-Tooth disease : opportunities and challenges
    Pipis M [2019]
  • New developments in Charcot-Marie-Tooth neuropathy and related diseases
    Pareyson D [2017]
  • Neurotrophins : roles in neuronal development and function
    Huang EJ [2001]
  • Neuregulin 1 type III improves peripheral nerve myelination in a mouse model of congenital hypomyelinating neuropathy
    Belin S [2019]
  • NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients
    Sahenk Z [2005]
  • Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy
    Senderek J [2003]
  • Mutation analysis of MFN2, GJB1, MPZ and PMP22 in Italian patients with axonal Charcot-Marie-Tooth disease
    Bergamin G [2014]
  • MicroRNAs: genomics, biogenesis, mechanism, and function
    Bartel DP [2004]
  • MicroRNA-deficient Schwann cells display congenital hypomyelination
    Yun B [2010]
  • MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A
    Rocha AG [2018]
  • Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy
    Kagiava A [2016]
  • Intraneural GJB1gene delivery improves nerve pathology in a model of Xlinked Charcot-Marie-Tooth disease
  • Integration site and clonal expansion in human chronic retroviral infection and gene therapy
    Niederer HA [2014]
  • Inherited neuropathies : clinical overview and update
    Klein CJ [2013]
  • Identification of drug modulators targeting genedosage disease CMT1A
    Jang SW [2012]
  • High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A : results of a randomized, double-masked, controlled trial
    Lewis RA [2013]
  • Hereditary neuropathies
    Eggermann K [2018]
  • HDAC6inhibitors rescued the defective axonal mitochondrial movement in motor neurons derived from the induced pluripotent stem cells of peripheral neuropathy patients with HSPB1 mutation
    Kim JY [2016]
  • HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease
    Benoy V [2018]
  • HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease
  • Genetic aspects of hereditary motor and sensory neuropathy(types I and II)
    Harding AE [1980]
  • Gene silencing in mammals by small interfering RNAs
    McManus MT [2002]
  • Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy
    Schiza N [2019]
  • Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X
    Kagiava A [2019]
  • Gene delivery to rat and human Schwann cells and nerve segments : a comparison of AAV 1-9 and lentiviral vectors
    Hoyng SA [2015]
  • Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment : an open-label, phase 2, dose-escalation study
    Cirak S [2011]
  • Enzyme-responsive nanomaterials for controlled drug delivery
    Hu Q [2014]
  • Endogenous BDNF is required for myelination and regeneration of injured sciatic nerve in rodents
    Zhang JY [2000]
  • Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A(CMT1A)
    Prukop T [2019]
  • Dicer in Schwann cells is required for myelination and axonal integrity
    Pereira JA [2010]
  • Developmental loss of NT-3 in vivo results in reduced levels of myelin-specific proteins, a reduced extent of myelination and increased apoptosis of Schwann cells
    Woolley AG [2008]
  • Development of improved HDAC6 inhibitors as pharmacological therapy for axonal Charcot-Marie-Tooth disease
    Benoy V [2017]
  • Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB
    Meier C [1999]
  • Design of polymeric gene carriers for effective intracellular delivery
    Lai WF [2018]
  • DNA duplication associated with Charcot-Marie-Tooth disease type 1A
    Lupski JR [1991]
  • Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zerotruncating mutants
    Khajavi M [2005]
  • Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice
    Huxley C [1998]
  • Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA
    Huxley C [1996]
  • Connexin32 is a myelin-related protein in the PNS and CNS
    Scherer SS [1995]
  • Connexin mutations in X-linked Charcot-Marie-Tooth disease
    Bergoffen J [1993]
  • Coenzyme Q10 therapy in hereditary motor sensory neuropathy type VI with novel mitofusin 2 mutation
    Takahashi R [2012]
  • Clinical gene therapy for neurodegenerative diseases : past, present, and future
    Piguet F [2017]
  • Clinical characterization and genetic analysis of Korean patients with X-linked Charcot-Marie-Tooth disease type 1
    Hong YB [2017]
  • Charcot-Marie-Tooth disease subtypes and genetic testing strategies
    Saporta AS [2011]
  • Charcot-Marie-Tooth disease : frequency of genetic subtypes and guidelines for genetic testing
    Murphy SM [2012]
  • Cas9 as a versatile tool for engineering biology
    Mali P [2013]
  • CRISPR/Cas9 for genome editing : progress, implications and challenges
    Zhang, F. [2014]
  • CRISPR/Cas-mediated base editing : technical considerations and practical applications
    Molla KA [2019]
  • Biochemical characterization of protein quality control mechanisms during disease progression in the C22 mouse model of CMT1A
    Chittoor VG [2013]
  • Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease
    Passage E [2004]
  • Ascorbic acid in Charcot-Marie-Tooth disease type 1A(CMT-TRIAAL and CMT-TRAUK) : a double-blind randomised trial
    Pareyson D [2011]
  • Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children : a randomised, doubleblind, placebo-controlled, safety and efficacy trial
    Burns J [2009]
  • Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
    Mann CJ [2001]
  • Antisense-based therapy for the treatment of spinal muscular atrophy
    Rigo F [2012]
  • Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy
  • An exploratory randomised doubleblind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol(PXT3003)in patients with Charcot-Marie-Tooth disease type 1A
    Attarian S [2014]
  • Allele-specific silencing of Alzheimer's disease genes : the amyloid precursor protein genes with Swedish or London mutations
    Feng X [2006]
  • Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo
    Xia X [2006]
  • Ablation of Dicer from murine Schwann cells increases their proliferation while blocking myelination
    Bremer J [2010]
  • AAV1.NT-3 gene therapy for Charcot-Marie-Tooth neuropathy
    Sahenk Z [2014]
  • A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2
    Monani UR [1999]
  • A reversible RNA onswitch that controls gene expression of AAV-delivered therapeutics in vivo
    Zhong G [2020]